Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________. HOOKIPA PHARMA INC. (Exact Name of Registrant as Specified in its Charter) Delaware 81-5395687 (State or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38869 HOOKIPA PHARMA INC. (Exact name of registrant as specified in its charter) Delaware 81-5395687 (State of Other Jurisdiction of incorporation or Organizat ...

Group 1 - HOOKIPA Pharma Inc. has announced that it does not intend to make an offer for Poolbeg Pharma plc following non-binding discussions for an all-share acquisition [3] - The announcement is made in accordance with Rule 2.8 of the City Code on Takeovers and Mergers [3][4] - The Board of HOOKIPA had previously extended discussions regarding the potential acquisition, but has now decided against proceeding [3] Group 2 - HOOKIPA and associated parties reserve the right to set aside restrictions under Rule 2.8 under certain circumstances, including agreement from Poolbeg's board or a firm intention to make an offer by a third party [4] - The announcement constitutes inside information as per the Market Abuse Regulation [2]

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial Primary completion expected H2 2025 NEW YORK and VIENNA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage ...

NEW YORK and VIENNA, Austria, Jan. 08, 2025 (GLOBE NEWSWIRE) -- FORM 8 (OPD) PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFERRules 8.1 and 8.2 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:HOOKIPA Pharma Inc.(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c) Name of offeror/offeree in relat ...

NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the treatment of cancer and serious infectious disease, today announced a notice to shareholders regarding U.K. disclosure requirements. HOOKIPA directs the attention of its shareholders to certain disclosure requirements applicable to the potential all-share acquisition by HOOKIPA of Poolbeg ...

Potential Combination Update - Poolbeg Pharma and HOOKIPA Pharma are in discussions regarding a potential combination, with significant shareholder Gilead Sciences indicating its intention to vote in favor of the deal if a formal offer is made [2][3] - Gilead owns 1,875,947 HOOKIPA common shares, representing 19.4% of HOOKIPA's existing issued share capital [3] Fundraise Details - HOOKIPA has amended the details of its planned Fundraise, now expecting to undertake a 100% primary private placement fundraise of approximately $30 million+, up from the previously stated $30 million [4] - Oppenheimer & Co Inc has been engaged as the placement agent for the private placement fundraise [5] Advisors and Contacts - Poolbeg has engaged Cavendish Capital Markets, Canaccord Genuity, Shore Capital, and J&E Davy as financial advisers and brokers [6][7][14][15] - HOOKIPA has engaged Moelis & Company as its financial adviser [8][16] - Contact details for key executives and investor relations teams at both companies are provided [6][7]

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 6 January 2025 HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment    NEW YORK and VIENNA, Austria, Jan. 06, 2025 (GLOBE NEWSWIRE) -- The following amendment has been made to the ‘Rule 2.9 Information’ disclosed by HOOKIPA in the Rule 2.4 announcement made on 2 January 2025 regarding the poten ...

Financial Performance - The company reported a net loss of $13.8 million and $18.6 million for the three and nine months ended September 30, 2024, respectively, with an accumulated deficit of $387.8 million [151]. - The net loss for the three months ended September 30, 2024, was $13.8 million, an improvement of $5.2 million compared to a net loss of $19.1 million in the same period of 2023 [200]. - The net loss for the nine months ended September 30, 2024, was $18.6 million, compared to a net loss of $56.8 million for the same period in 2023 [229][230]. - The accumulated deficit as of September 30, 2024, was $387.8 million, with expectations of continued significant losses for the foreseeable future [218]. - The company does not expect positive cash flows from operations in the foreseeable future and anticipates incurring net operating losses for at least the next several years [214]. - Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the issuance date of the financial statements [216]. Revenue and Income - Revenue from collaboration and licensing was $4.7 million for the three months ended September 30, 2024, down from $6.9 million in the same period of 2023, representing a decrease of approximately 31.6% [182]. - For the nine months ended September 30, 2024, revenue increased to $42.6 million from $12.7 million in 2023, marking an increase of approximately 234.6% [182]. - The company recognized $36.4 million in revenue related to the terminated Roche Collaboration Agreement during the nine months ended September 30, 2024 [190]. - Other income for the three months ended September 30, 2024, was $1.8 million, compared to other expenses of $0.8 million for the same period in 2023, primarily due to exchange rate differences [205]. - For the nine months ended September 30, 2024, other income was $1.3 million, compared to other expenses of $1.0 million for the same period in 2023, also attributed to exchange rate differences [206]. Expenses - Research and development expenses for the three months ended September 30, 2024, totaled $15.6 million, compared to $24.6 million for the same period in 2023 [168]. - Total research and development expenses for the nine months ended September 30, 2024, were $55.5 million, compared to $65.3 million for the same period in 2023 [168]. - The company expects research and development expenses to increase substantially as it advances existing and future product candidates through clinical trials [165]. - General and administrative expenses increased to $6.7 million for the three months ended September 30, 2024, compared to $4.9 million in 2023, an increase of approximately 36.7% [195]. - Restructuring expenses for the three months ended September 30, 2024, were $0.9 million, with $0.8 million attributed to severance and other personnel costs [198]. - The company has established a full valuation allowance for deferred tax assets as of September 30, 2024, due to uncertainty in realizing benefits [180]. Cash and Funding - The company has cash, cash equivalents, and restricted cash of $60.0 million as of September 30, 2024 [147]. - Cash used in operating activities for the nine months ended September 30, 2024, was $56.0 million, an increase from $46.3 million in the same period of 2023 [229][230]. - Cash used in investing activities decreased to $0.2 million in the nine months ended September 30, 2024, from $3.7 million in the same period of 2023 [231][232]. - Cash used in financing activities was $1.3 million for the nine months ended September 30, 2024, compared to cash provided of $44.4 million in the same period of 2023 [233][234]. - The company anticipates requiring additional funding to support clinical and preclinical development, regulatory approvals, and operational expansions [219]. - The company has no committed external source of funds for its development efforts and expects to finance future cash needs through a combination of equity offerings, debt financings, and collaborations [225]. Research and Development - The eseba-vec program for HPV16+ head and neck cancers showed an overall response rate (ORR) of 55.0% in the selected Phase 3 dose group, with a disease control rate (DCR) of 75% [137]. - The combination treatment of eseba-vec with pembrolizumab demonstrated a favorable safety profile, with serious adverse events in only 7.6% of participants [139]. - The company received FDA clearance for HB-700 in April 2024, targeting KRAS mutated cancers, including lung, colorectal, and pancreatic cancers [140]. - The collaboration with Gilead for the HBV program has the potential for up to $185.0 million in milestone payments, plus tiered royalties [142]. - The company regained full control of the HB-700 program after Roche terminated their collaboration agreement, receiving a non-refundable upfront payment of $25.0 million and milestone payments of $20.0 million [141]. - The company regained full control of the intellectual property portfolio associated with the terminated Roche Collaboration Agreement effective April 25, 2024 [158]. - The company recognized $0.6 million in cost reimbursements for research and development activities related to a first human trial [160]. Market Risks - The company is subject to market risks from changes in interest rates, foreign exchange rates, and inflation, which may impact financial performance [241][243]. - The company anticipates that a significant portion of its expenses will continue to be denominated in euros, exposing it to foreign currency risk [241].

Clinical Trials - Enrollment of 68 patients completed in Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC, four months ahead of schedule[1] - First patients dosed in Phase 2 investigator-initiated study for eseba-vec in adjuvant therapy for head and neck cancer[3] - The HB-700 program is ready for Phase 1 trials, targeting KRAS-mutated cancers, with FDA clearance received in April 2024[5] - HOOKIPA received a $5 million milestone payment from Gilead in July 2024 related to the HB-500 clinical trial[12] Financial Performance - Revenue for Q3 2024 was $4.7 million, a decrease of 31.6% from $6.9 million in Q3 2023, primarily due to lower partnering revenues[14] - Net loss for Q3 2024 was $13.8 million, compared to a net loss of $19.1 million in Q3 2023, representing a 27.3% improvement[18] Expenses - Research and development expenses decreased to $15.6 million in Q3 2024 from $24.6 million in Q3 2023, reflecting lower personnel and laboratory-related expenses[15] - General and administrative expenses increased to $6.7 million in Q3 2024 from $4.9 million in Q3 2023, driven by higher personnel-related expenses and consulting fees[16] Cash Position - Cash position as of September 30, 2024, was $60.0 million, down from $117.5 million as of December 31, 2023, primarily due to cash used in operating activities[13] - As of September 30, 2024, cash, cash equivalents, and restricted cash totaled $59,957,000, down from $117,521,000 as of December 31, 2023[24] Assets and Liabilities - Total assets decreased to $109,730,000 from $161,337,000[24] - Total liabilities reduced to $37,928,000 compared to $71,480,000[24] - Total stockholders' equity declined to $71,802,000 from $89,857,000[24] Corporate Actions - A reverse stock split of 1-for-10 was executed on July 9, 2024, to comply with Nasdaq listing requirements[11]